がん/腫瘍プロファイリング市場：技術、バイオマーカータイプ、がんタイプ、アプリケーション別-2025-2030年の世界予測

がん/腫瘍プロファイリング市場は、2023年に107億9,000万米ドルと評価され、2024年には127億7,000万米ドルに達すると予測され、CAGR 18.74％で成長し、2030年には359億4,000万米ドルに達すると予測されています。

がん/腫瘍プロファイリングがん細胞を遺伝子および分子レベルで包括的に分析することで、腫瘍の不均一性の複雑さを理解し、個別化治療戦略を容易にします。がんプロファイリングの必要性は、がん専門医が個々のバイオマーカーに基づいて治療を調整し、治療成績を向上させ、副作用を最小限に抑えることを可能にする精密医療における重要な役割から生じる。その用途は臨床診断、創薬、腫瘍学研究に及び、エンドユーザーは病院、診断研究所、研究機関、製薬会社です。市場成長の主な原動力は、がんの有病率の増加、次世代シーケンシング（NGS）などのプロファイリング技術の進歩、個別化医療に対する需要の高まりです。特に、ハイスループット技術へのシフトと費用対効果の高いプロファイリング手法の開発は、業界拡大の大きなチャンスとなっています。さらに、標的療法を強化するための製薬企業と技術開発企業との提携は、市場の成長を促進する可能性があります。しかし、高度なシーケンシングプラットフォームに関連する高コスト、データプライバシーに関する懸念、熟練した専門家の不足といった課題が、大きな障害となっています。さらに、規制の複雑さや償還の問題がさらなる障壁となっています。技術革新の可能性がある分野は、データの解釈と予測モデリングを強化するための統合バイオインフォマティクス・ソリューションとAI主導型アナリティクスの開発にあります。リキッドバイオプシーや非侵襲的プロファイリング法の研究開発努力が拡大すれば、投資家にとっても開発者にとっても新たな展望が開ける可能性があります。市場はダイナミックに進化しており、包括的なデータセットを活用して確かな臨床的洞察を得ようとする分野横断的な連携が動向を見せています。新たなビジネスチャンスを生かすために、利害関係者はプロファイリング技術へのアクセス性と手頃な価格の向上、戦略的提携の構築、スキルギャップを埋めるための人材育成プログラムへの投資に重点を置くべきです。持続的な成長は、世界の規制状況に合致し、がん治療の多様なニーズに応えるイノベーションを促進することで実現できると思われます。

市場力学：急速に進化するがん/腫瘍プロファイリング市場の主要市場インサイトを公開

がん/腫瘍プロファイリング市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん患者の治療にバイオマーカーの採用が増加
  • がん診断法を考案するための政府機関や世界的組織のイニシアチブの利用可能性
  • がん治療における個別化医療への嗜好の高まり
• 市場抑制要因
  • がん/腫瘍プロファイリング機器およびサービスへの高額な設備投資
• 市場機会
  • 次世代シーケンサーの登場と腫瘍プロファイリングの進歩
  • がん検出を改善するためのポイントオブケア診断技術の向上
• 市場の課題
  • バイオマーカー発見から承認までの比率の低さ

ポーターの5つの力：がん/腫瘍プロファイリング市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん/腫瘍プロファイリング市場における外部からの影響の把握

外部マクロ環境要因は、がん/腫瘍プロファイリング市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん/腫瘍プロファイリング市場における競合情勢の把握

がん/腫瘍プロファイリング市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん/腫瘍プロファイリング市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん/腫瘍プロファイリング市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん患者の治療におけるバイオマーカーの採用増加
    • がん診断法の開発に向けた政府および国際機関の取り組みの有無
    • がん治療における個別化医療への関心の高まり
  • 抑制要因
    • がん/腫瘍プロファイリング機器およびサービスへの多額の資本投資
  • 機会
    • 次世代シーケンシングの出現と腫瘍プロファイリングの進歩
    • がん検出を向上させるためのポイントオブケア診断技術の改善
  • 課題
    • バイオマーカーの発見から承認までの比率が低い
• 市場セグメンテーション分析
  • 技術：次世代シーケンシング（NGS）を活用した様々ながんの遺伝子変異の探索
  • バイオマーカーの種類：遺伝子の発現、遺伝子機能、遺伝子調節の測定にゲノムバイオマーカーを使用する
  • がんの種類：予測モデルと臨床リスク層別化のための前立腺がんのがんプロファイリングが広く推奨されています
  • 応用：治癒と回復時間を改善するための精密医療の開発におけるがん/腫瘍プロファイリングの使用の増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん/腫瘍プロファイリング市場：技術別

• 免疫測定
• インサイチューハイブリダイゼーション
• 質量分析
• マイクロアレイ
• 次世代シーケンシング
• ポリメラーゼ連鎖反応

第7章 がん/腫瘍プロファイリング市場バイオマーカーの種類別

• ゲノムバイオマーカー
• タンパク質バイオマーカー

第8章 がん/腫瘍プロファイリング市場がんの種類別

• 乳がん
• 大腸がん
• 肺がん
• メラノーマがん
• 前立腺がん

第9章 がん/腫瘍プロファイリング市場：用途別

• バイオマーカーの発見
• 臨床応用
• 診断
• パーソナライズ医療
• 予測
• 調査
• スクリーニング
• 治療とモニタリング

第10章 南北アメリカのがん/腫瘍プロファイリング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のがん/腫瘍プロファイリング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのがん/腫瘍プロファイリング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • アジレントとNCCS、アジアで多くみられるがんに関するシンガポールのゲノムプロファイリングを推進するための調査協力契約を締結
  • ソフィア・ジェネティクス、アジレントとがん分析製品で提携
  • Point32HealthとFoundation Medicineが進行がん患者への包括的ゲノムプロファイリングへのアクセスを拡大
  • シナジーラボラトリーズ、新たながんプロファイリングソリューションにSOPHiA GENETICSの技術を採用
  • Exact Sciences、米国でOncoExTraがん治療選択検査を開始
  • カリスライフサイエンス、4億米ドルの調達で総資金調達額20億米ドルに迫る
  • Prenetics所有のACT GenomicsがACTOncoのFDA認可を取得
  • アジレント、がん調査向け高性能NGSターゲットエンリッチメントワークフローの開発会社Avida Biomedの買収を発表
  • プレネティクスがACTゲノミクスを買収
  • ロシュ社、エンハートゥの適応となるHER2低発現転移性乳がん患者を特定するための初のコンパニオン診断薬でFDAの承認を取得
  • CDC、がんムーンショット目標の推進に2億1,500万米ドルを授与

企業一覧

• Takara Bio Inc.
• Nonacus Limited
• GenScript Biotech Corporation
• Tempus Labs Inc.
• Thermo Fisher Scientific Inc.
• Hologic, Inc.
• 4basecare Onco Solutions Private Limited
• Personalis, Inc.
• Merck KGaA
• Exact Sciences Corporation
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Lucence Health, Inc.
• Guardant Health, Inc.
• Sysmex Corporation
• Agendia, Inc.
• Paragon Genomics, Inc.
• F. Hoffmann-La Roche Ltd.
• HTG Molecular Diagnostics, Inc.
• NanoString Technologies, Inc.
• Predictive Oncology Inc.
• IMBdx, Inc.
• Perthera, Inc.
• GENINUS Inc.
• Genomic Life
• ACT Genomics Co., Ltd. by Prenetics Global Limited
• BostonGene Corporation
• Caris Life Sciences
• Strand Life Sciences
• Neogenomics, Inc.
• Agilent Technologies, Inc.
• Oncompass Medicine Hungary Kft.
• OncoDNA S.A.

LIST OF FIGURES

• FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
• FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER/TUMOR PROFILING MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 46. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 72. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 73. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 74. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 81. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 85. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 86. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 88. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 89. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 90. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 97. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 98. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 101. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 102. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 105. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 106. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 109. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 110. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 116. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 117. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 118. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 119. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 121. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 122. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 123. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 126. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 127. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 130. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 131. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 133. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 134. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 135. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 138. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 139. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 142. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 143. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 149. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 150. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 151. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 153. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 154. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 155. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 157. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 158. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 159. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 162. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 163. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 165. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 166. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 167. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 177. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 181. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 182. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 183. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 186. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 187. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 189. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 190. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 191. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 198. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 199. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 201. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer/Tumor Profiling Market was valued at USD 10.79 billion in 2023, expected to reach USD 12.77 billion in 2024, and is projected to grow at a CAGR of 18.74%, to USD 35.94 billion by 2030.

Cancer/tumor profiling encompasses a comprehensive analysis of the cancerous cells at a genetic and molecular level, which aids in understanding the complexities of tumor heterogeneity and facilitates personalized treatment strategies. The necessity of cancer profiling arises from its critical role in precision medicine, enabling oncologists to tailor treatments based on individual biomarkers, thus improving therapeutic outcomes and minimizing adverse effects. Its applications span across clinical diagnostics, drug discovery, and oncology research, with end-users comprising hospitals, diagnostic laboratories, research institutes, and pharmaceutical companies. Market growth is primarily driven by the increasing prevalence of cancer, advancements in profiling technologies such as next-generation sequencing (NGS), and heightened demand for personalized medicine. Particularly, the shift towards high-throughput technologies and the development of cost-effective profiling methods present vast opportunities for industry expansion. Additionally, partnerships between pharmaceutical firms and technology developers to enhance targeted therapies could fuel market growth. However, challenges such as high costs associated with advanced sequencing platforms, data privacy concerns, and a dearth of skilled professionals act as significant hindrances. Furthermore, regulatory complexities and reimbursement issues pose additional barriers. Potential areas of innovation lie in the development of integrated bioinformatics solutions and AI-driven analytics to enhance data interpretation and predictive modeling. Expanding R&D efforts in liquid biopsy and non-invasive profiling methods could open new vistas for investors and developers alike. The market is dynamic and evolving, with a trend towards cross-disciplinary collaboration to leverage comprehensive datasets for robust clinical insights. To capitalize on emerging opportunities, stakeholders should focus on enhancing the accessibility and affordability of profiling techniques, building strategic alliances, and investing in workforce training programs to bridge the skill gap. Sustainable growth could be realized by fostering innovations that align with global regulatory standards and meet the diverse needs of the oncology treatment landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer/Tumor Profiling Market

The Cancer/Tumor Profiling Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing adoption of biomarkers to treat cancer patients
  • Availability of government and global organizations' initiatives for devising cancer diagnosing methods
  • Surging preference for personalized medicines for cancer treatment
• Market Restraints
  • High capital investment in cancer/tumor profiling instruments and services
• Market Opportunities
  • Emergence of next-generation sequencing and advancements in tumor profiling
  • Improvements in point-of-care diagnostic technologies to improve cancer detection
• Market Challenges
  • Low biomarker discovery-to-approval ratio

Porter's Five Forces: A Strategic Tool for Navigating the Cancer/Tumor Profiling Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer/Tumor Profiling Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer/Tumor Profiling Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer/Tumor Profiling Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer/Tumor Profiling Market

A detailed market share analysis in the Cancer/Tumor Profiling Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer/Tumor Profiling Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer/Tumor Profiling Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Nonacus Limited, GenScript Biotech Corporation, Tempus Labs Inc., Thermo Fisher Scientific Inc., Hologic, Inc., 4basecare Onco Solutions Private Limited, Personalis, Inc., Merck KGaA, Exact Sciences Corporation, Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Guardant Health, Inc., Sysmex Corporation, Agendia, Inc., Paragon Genomics, Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc., NanoString Technologies, Inc., Predictive Oncology Inc., IMBdx, Inc., Perthera, Inc., GENINUS Inc., Genomic Life, ACT Genomics Co., Ltd. by Prenetics Global Limited, BostonGene Corporation, Caris Life Sciences, Strand Life Sciences, Neogenomics, Inc., Agilent Technologies, Inc., Oncompass Medicine Hungary Kft., and OncoDNA S.A..

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, and Polymerase Chain Reaction.
• Based on Biomarker Type, market is studied across Genomic Biomarker and Protein Biomarker.
• Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, and Prostate Cancer.
• Based on Application, market is studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
    • 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
    • 5.1.1.3. Surging preference for personalized medicines for cancer treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
    • 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
  • 5.1.4. Challenges
    • 5.1.4.1. Low biomarker discovery-to-approval ratio
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
  • 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
  • 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
  • 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer/Tumor Profiling Market, by Technology

• 6.1. Introduction
• 6.2. Immunoassays
• 6.3. In-Situ Hybridization
• 6.4. Mass Spectrometry
• 6.5. Microarrays
• 6.6. Next-Generation Sequencing
• 6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

• 7.1. Introduction
• 7.2. Genomic Biomarker
• 7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

• 8.1. Introduction
• 8.2. Breast Cancer
• 8.3. Colorectal Cancer
• 8.4. Lung Cancer
• 8.5. Melanoma Cancer
• 8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

• 9.1. Introduction
• 9.2. Biomarker Discovery
• 9.3. Clinical Application
• 9.4. Diagnostics
• 9.5. Personalized Medicine
• 9.6. Prognostics
• 9.7. Research
• 9.8. Screening
• 9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
  • 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
  • 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
  • 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
  • 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
  • 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
  • 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
  • 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
  • 13.3.9. Prenetics Acquires ACT Genomics
  • 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
  • 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals

Companies Mentioned

• 1. Takara Bio Inc.
• 2. Nonacus Limited
• 3. GenScript Biotech Corporation
• 4. Tempus Labs Inc.
• 5. Thermo Fisher Scientific Inc.
• 6. Hologic, Inc.
• 7. 4basecare Onco Solutions Private Limited
• 8. Personalis, Inc.
• 9. Merck KGaA
• 10. Exact Sciences Corporation
• 11. Illumina, Inc.
• 12. Laboratory Corporation of America Holdings
• 13. Lucence Health, Inc.
• 14. Guardant Health, Inc.
• 15. Sysmex Corporation
• 16. Agendia, Inc.
• 17. Paragon Genomics, Inc.
• 18. F. Hoffmann-La Roche Ltd.
• 19. HTG Molecular Diagnostics, Inc.
• 20. NanoString Technologies, Inc.
• 21. Predictive Oncology Inc.
• 22. IMBdx, Inc.
• 23. Perthera, Inc.
• 24. GENINUS Inc.
• 25. Genomic Life
• 26. ACT Genomics Co., Ltd. by Prenetics Global Limited
• 27. BostonGene Corporation
• 28. Caris Life Sciences
• 29. Strand Life Sciences
• 30. Neogenomics, Inc.
• 31. Agilent Technologies, Inc.
• 32. Oncompass Medicine Hungary Kft.
• 33. OncoDNA S.A.